SGLT2 inhibitors are a class of medications that inhibit sodium-glucose transport proteins in the nephron, unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. From Wikipedia
Recent research highlights a significant reduction in Alzheimer's and dementia risk for type 2 diabetes patients using GLP-1 receptor agonists, while emphasizing the need for further trials.
